Market Intelligence, Clinical Progress, and High-Purity Reagents for Telomere Biology Disorders and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PARN drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PARN Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Sf9/HEK293 expressed for optimal folding. |
View PARN Products |
| Gene Delivery | PARN Promise-ORF / Lentivirus Full-length ORF for stable cell lines and deadenylation functional assays. |
View PARN Products |
| Benchmark Ab | Anti-PARN Antibody Recombinant positive control for Western Blot, IHC, and IP validation. |
View PARN Products |
| Validator | PARN siRNA Set For knockdown verification in target engagement and functional studies. |
View PARN Products |
| Related Target A | TERT (Telomerase Reverse Transcriptase) Synergistic partner in telomere maintenance; mutated in overlapping bone marrow failure syndromes. |
View TERT Products |
| Related Target B | CNOT1 (CCR4-NOT Transcription Complex Subunit 1) Core deadenylase scaffold; crucial counter-screening target for selectivity assays. |
View CNOT1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Deadenylation Activity Assay | Highly active recombinant PARN protein, sequence verified and purified under nuclease-free conditions to ensure assay specificity. |
| Selectivity Counter-Screening | Deadenylase panel proteins (CNOT1, CNOT7, PAN2) available, strictly verified by mass spectrometry for cross-reactivity profiling. |
| Lack of Controls | Recombinant positive control antibodies and validated siRNA sets included for target validation. |
| False Positives in HTS | High-purity, endotoxin-controlled formulations reduce non-specific binding in microplate assays. |
Live PARN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PARN therapeutics is intensifying, with major players shifting focus from traditional oncology targets to RNA-targeted and telomere-restoring modalities. As first-generation therapies reach preclinical validation, the next wave of R&D is targeting selective small-molecule inhibitors in oncology and gene correction therapies for telomere biology disorders (TBDs).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | Glioblastoma, Breast Cancer | Enzymatic Activity Assay (Need highly active, sequence-verified PARN protein) |
| Gene Therapy / mRNA | Rare Disease Biotechs | Dyskeratosis Congenita, Idiopathic Pulmonary Fibrosis | Expression & Functional Rescue Validation (Need Lentivirus for stable cell lines) |
| RNA-Targeted Oligos | RNA Therapeutics Companies | Myelodysplastic Syndromes (MDS) | Selectivity Assay (Need CNOT1/PAN2 counter-screening panels) |